FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2886917823> ?p ?o ?g. }

• W2886917823 endingPage "e421" @default.
• W2886917823 startingPage "e411" @default.
• W2886917823 abstract "Background Front-line therapy for elderly or unfit patients with acute myeloid leukaemia (AML) remains unsatisfactory with poor outcomes and excessive toxicity. We studied a new low-intensity regimen of cladribine combined with low-dose cytarabine alternating with decitabine, aimed at improving outcomes in this population. Based on our previous experience, we hypothesised that this combination would be safe and more effective than current approaches with hypomethylating agents. Methods In this single-arm, open-label, single-centre phase 2 study, we enrolled patients aged 60 years or older with previously untreated AML or high-risk myelodysplastic syndrome who had adequate organ function and an Eastern Cooperative Oncology Group performance status of 2 or less. Patients were treated with cladribine plus low-dose cytarabine for two 28-day cycles alternating with decitabine for two 28-day cycles, for up to 18 cycles. Induction therapy (cycle 1) consisted of cladribine 5 mg/m2 intravenously over 1–2 h on days 1–5 and cytarabine 20 mg subcutaneously twice daily on days 1–10. Patients who had remission during this induction regimen moved on to consolidation therapy (cladribine 5 mg/m2 intravenously over 1–2 h on days 1–3 and cytarabine 20 mg twice daily on days 1–10, alternating with decitabine 20 mg/m2 intravenously on days 1–5). The primary outcome measure was disease-free survival. Secondary outcomes were overall survival, proportion of patients achieving complete response, proportion of patients achieving response, toxicity, and induction mortality. All treated patients were included in the analyses. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01515527. Findings Between Feb 17, 2012, and July 6, 2017, 118 patients were enrolled and treated, among whom 48 (41%) had an adverse karyotype, 20 (17%) had therapy-related AML, 18 (15%) had treated secondary AML, and 20 (17%) had TP53 mutations. Median disease-free survival was 10·8 months (IQR 5·4–25·9). 80 (68%) patients achieved objective response: 69 (58%) achieved a complete response and 11 (9%) patients had complete response with incomplete count recovery. The median overall survival was 13·8 months (6·9–28·6). The regimen was well tolerated, with one (1%) death within the first 4 weeks and eight (7%) deaths within the first 8 weeks. The most common non-haematological adverse events of grade 3 or worse were infection (88 [75%] patients), elevated total bilirubin (26 [22%] patients), rash (13 [11%] patients), and nausea (13 [11%] patients). Interpretation The combination of cladribine and low-dose cytarabine alternating with decitabine appears to be a safe and highly effective regimen for the treatment of elderly or unfit patients with newly diagnosed AML. Further testing of this regimen is warranted, and could help to provide a new, effective option for reduced-intensity therapy in this population. Funding Part supported by the National Institutes of Health." @default.
• W2886917823 created "2018-08-22" @default.
• W2886917823 creator A5000750846 @default.
• W2886917823 creator A5010663972 @default.
• W2886917823 creator A5010786159 @default.
• W2886917823 creator A5011548707 @default.
• W2886917823 creator A5015140142 @default.
• W2886917823 creator A5020340537 @default.
• W2886917823 creator A5022647201 @default.
• W2886917823 creator A5028591457 @default.
• W2886917823 creator A5028845635 @default.
• W2886917823 creator A5029750735 @default.
• W2886917823 creator A5035605515 @default.
• W2886917823 creator A5039074657 @default.
• W2886917823 creator A5046135731 @default.
• W2886917823 creator A5049385583 @default.
• W2886917823 creator A5055045706 @default.
• W2886917823 creator A5058755419 @default.
• W2886917823 creator A5061026876 @default.
• W2886917823 creator A5070904381 @default.
• W2886917823 creator A5071687115 @default.
• W2886917823 creator A5074515976 @default.
• W2886917823 creator A5084290698 @default.
• W2886917823 creator A5085521139 @default.
• W2886917823 creator A5088307376 @default.
• W2886917823 creator A5090435894 @default.
• W2886917823 date "2018-09-01" @default.
• W2886917823 modified "2023-10-18" @default.
• W2886917823 title "Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial" @default.
• W2886917823 cites W1556454749 @default.
• W2886917823 cites W1572539757 @default.
• W2886917823 cites W1585096943 @default.
• W2886917823 cites W1600365609 @default.
• W2886917823 cites W163194523 @default.
• W2886917823 cites W1645524462 @default.
• W2886917823 cites W1977917277 @default.
• W2886917823 cites W1982770189 @default.
• W2886917823 cites W2007386979 @default.
• W2886917823 cites W2010026460 @default.
• W2886917823 cites W2028627376 @default.
• W2886917823 cites W2051987542 @default.
• W2886917823 cites W2053968609 @default.
• W2886917823 cites W2058188142 @default.
• W2886917823 cites W2067954981 @default.
• W2886917823 cites W2069448515 @default.
• W2886917823 cites W2092335024 @default.
• W2886917823 cites W2093883889 @default.
• W2886917823 cites W2096748176 @default.
• W2886917823 cites W2106084333 @default.
• W2886917823 cites W2110893339 @default.
• W2886917823 cites W2115139696 @default.
• W2886917823 cites W2139984188 @default.
• W2886917823 cites W2142830602 @default.
• W2886917823 cites W2149058047 @default.
• W2886917823 cites W2157287007 @default.
• W2886917823 cites W2160968219 @default.
• W2886917823 cites W2171484579 @default.
• W2886917823 cites W2288894655 @default.
• W2886917823 cites W2419140434 @default.
• W2886917823 cites W2559537906 @default.
• W2886917823 cites W2623089849 @default.
• W2886917823 cites W2715749014 @default.
• W2886917823 cites W2738685991 @default.
• W2886917823 cites W2760499085 @default.
• W2886917823 cites W2783500974 @default.
• W2886917823 cites W2783671270 @default.
• W2886917823 cites W2806682325 @default.
• W2886917823 doi "https://doi.org/10.1016/s2352-3026(18)30132-7" @default.
• W2886917823 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6775639" @default.
• W2886917823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30115541" @default.
• W2886917823 hasPublicationYear "2018" @default.
• W2886917823 type Work @default.
• W2886917823 sameAs 2886917823 @default.
• W2886917823 citedByCount "62" @default.
• W2886917823 countsByYear W28869178232018 @default.
• W2886917823 countsByYear W28869178232019 @default.
• W2886917823 countsByYear W28869178232020 @default.
• W2886917823 countsByYear W28869178232021 @default.
• W2886917823 countsByYear W28869178232022 @default.
• W2886917823 countsByYear W28869178232023 @default.
• W2886917823 crossrefType "journal-article" @default.
• W2886917823 hasAuthorship W2886917823A5000750846 @default.
• W2886917823 hasAuthorship W2886917823A5010663972 @default.
• W2886917823 hasAuthorship W2886917823A5010786159 @default.
• W2886917823 hasAuthorship W2886917823A5011548707 @default.
• W2886917823 hasAuthorship W2886917823A5015140142 @default.
• W2886917823 hasAuthorship W2886917823A5020340537 @default.
• W2886917823 hasAuthorship W2886917823A5022647201 @default.
• W2886917823 hasAuthorship W2886917823A5028591457 @default.
• W2886917823 hasAuthorship W2886917823A5028845635 @default.
• W2886917823 hasAuthorship W2886917823A5029750735 @default.
• W2886917823 hasAuthorship W2886917823A5035605515 @default.
• W2886917823 hasAuthorship W2886917823A5039074657 @default.
• W2886917823 hasAuthorship W2886917823A5046135731 @default.
• W2886917823 hasAuthorship W2886917823A5049385583 @default.
• W2886917823 hasAuthorship W2886917823A5055045706 @default.
• W2886917823 hasAuthorship W2886917823A5058755419 @default.
• W2886917823 hasAuthorship W2886917823A5061026876 @default.

• next